A Phase 3 interventional study of Bempedoic acid 180 mg tablet and Matching placebo tablet in Cardiovascular Diseases and Statin Adverse Reaction, sponsored by Esperion Therapeutics, Inc.. Completed at 1,332 sites in 32 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 13,970 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant-reported SI due to an adverse safety effect that started or increased during statin therapy and resolved or improved when statin therapy was discontinued resulting in an inability to tolerate:
Please note that participants currently tolerating very low dose statin therapy (an average daily dose of rosuvastatin \<5 mg, atorvastatin \<10 mg, simvastatin \<10 mg, lovastatin \<20 mg, pravastatin \<40 mg, fluvastatin \<40 mg, or pitavastatin \<2 mg) are considered to be intolerant to that low dose statin. Patients may continue taking very low dose statin therapy throughout the study provided that it is stable (used for at least 4 weeks prior to screening) and well tolerated.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bempedoic acid 180 mg tablet taken orally, once daily.
Drug: Bempedoic acid 180 mg tablet
Matching placebo tablet taken orally, once daily
Drug: Matching placebo tablet
Patients take bempedoic acid 180 mg tablet orally once daily
Also known as: ETC-1002
Patients take matching placebo tablet orally once daily
Also known as: placebo comparator
Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)
The primary efficacy end point was a four-component composite of adjudicated MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, as assessed in a time-to first-event analysis.
Time frame: Up to 68 months
Number of Participants With First Occurrence of Three Component MACE
The first key secondary end point was a three-component MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
Time frame: Up to 68 months
Number of Participants With First Occurrence of Myocardial Infarction
Number of participants with time to first occurrence of fatal and non-fatal myocardial infarction are presented.
Time frame: Up to 68 months
Number of Participants With Time to First Occurrence of Coronary Revascularization
Number of participants with time to first occurrence of coronary revascularization are presented.
Time frame: Up to 68 months
Number of Participants With Time to First Occurrence of Stroke
Number of participants with time to first occurrence of fatal and non-fatal stroke.
Time frame: Up to 68 months
Number of Participants With Time to Cardiovascular Death
Number of participants with time to cardiovascular death are presented.
Time frame: Up to 68 months
Number of Participants With Time to All-cause Mortality
All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.
Time frame: Up to 68 months
This was a randomized, double-blind, placebo-controlled, parallel-group study that assessed the occurrence of major adverse cardiovascular event (MACE) in participants with, or at high risk for, cardiovascular disease (CVD) who were unable to tolerate statin therapy.
| Milestone | Bempedoic Acid 180 Milligrams (mg) | Placebo Comparator |
|---|---|---|
| Started | 6992 | 6978 |
| Completed | 6697 | 6620 |
| Not completed | 295 | 358 |
| Withdrew: Withdrawal by subject | 170 | 196 |
| Withdrew: Physician decision | 3 | 5 |
| Withdrew: Lost to follow-up | 12 | 13 |
| Withdrew: Unclassifiable response | 105 | 139 |
| Withdrew: Administrative decision | 1 | 0 |
| Withdrew: Sponsor decision | 4 | 5 |
The primary efficacy end point was a four-component composite of adjudicated MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, as assessed in a time-to first-event analysis.
| Participants | Bempedoic Acid 180 mg | Placebo Comparator |
|---|---|---|
| Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE) | 819 | 927 |
The first key secondary end point was a three-component MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
| Participants | Bempedoic Acid 180 mg | Placebo Comparator |
|---|---|---|
| Number of Participants With First Occurrence of Three Component MACE | 575 | 663 |
Number of participants with time to first occurrence of fatal and non-fatal myocardial infarction are presented.
| Participants | Bempedoic Acid 180 mg | Placebo Comparator |
|---|---|---|
| Number of Participants With First Occurrence of Myocardial Infarction | 261 | 334 |
Number of participants with time to first occurrence of coronary revascularization are presented.
| Participants | Bempedoic Acid 180 mg | Placebo Comparator |
|---|---|---|
| Number of Participants With Time to First Occurrence of Coronary Revascularization | 435 | 529 |
Number of participants with time to first occurrence of fatal and non-fatal stroke.
| Participants | Bempedoic Acid 180 mg | Placebo Comparator |
|---|---|---|
| Number of Participants With Time to First Occurrence of Stroke | 135 | 158 |
Number of participants with time to cardiovascular death are presented.
| Participants | Bempedoic Acid 180 mg | Placebo Comparator |
|---|---|---|
| Number of Participants With Time to Cardiovascular Death | 269 | 257 |
All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.
| Participants | Bempedoic Acid 180 mg | Placebo Comparator |
|---|---|---|
| Number of Participants With Time to All-cause Mortality | 434 | 420 |
Collected over Up to 68 months. Serious adverse events (SAEs) and non-SAEs were collected from Safety Population. The Safety Population comprises of all randomized participants who received at least 1 dose of study medication (investigational product). Deaths were endpoints and not reported as SAEs. Negatively adjudicated non- fatal MACE events were reported as SAEs.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bempedoic Acid 180 mg | 437/7,001 (6.2%) | 1,767/7,001 (25.2%) | 5,805/7,001 (82.9%) |
| Placebo Comparator | 420/6,964 (6%) | 1,733/6,964 (24.9%) | 5,490/6,964 (78.8%) |
| Event | Bempedoic Acid 180 mg | Placebo Comparator |
|---|---|---|
| Atrial fibrillationCardiac disorders | 81/7001 | 95/6964 |
| COVID-19 pneumoniaInfections and infestations | 84/7001 | 90/6964 |
| PneumoniaInfections and infestations | 84/7001 | 81/6964 |
| Angina pectorisCardiac disorders | 56/7001 | 82/6964 |
| COVID-19Infections and infestations | 56/7001 | 75/6964 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 71/7001 | 69/6964 |
| Non-cardiac chest painGeneral disorders | 50/7001 | 57/6964 |
| Angina unstableCardiac disorders | 56/7001 | 53/6964 |
| Transient ischaemic attackNervous system disorders | 41/7001 | 36/6964 |
| Cardiac failure congestiveCardiac disorders | 39/7001 | 37/6964 |
| Event | Bempedoic Acid 180 mg | Placebo Comparator |
|---|---|---|
| HypertensionVascular disorders | 747/7001 | 804/6964 |
| COVID-19Infections and infestations | 731/7001 | 801/6964 |
| HyperuricaemiaMetabolism and nutrition disorders | 763/7001 | 393/6964 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 548/7001 | 554/6964 |
| Urinary tract infectionInfections and infestations | 539/7001 | 515/6964 |
| HeadacheNervous system disorders | 479/7001 | 493/6964 |
| MyalgiaMusculoskeletal and connective tissue disorders | 392/7001 | 470/6964 |
| Diabetes mellitusMetabolism and nutrition disorders | 458/7001 | 435/6964 |
| Back painMusculoskeletal and connective tissue disorders | 404/7001 | 450/6964 |
| Blood uric acid increasedInvestigations | 393/7001 | 186/6964 |
Intention-to-Treat Population is defined as all randomized participants.
| Age, Continuous(Years) | Bempedoic Acid 180 mg | Placebo Comparator | Total |
|---|---|---|---|
| Mean | 65.5 ± 9.0 | 65.5 ± 8.9 | 65.5 ± 9.0 |
| Sex: Female, Male(Participants) | Bempedoic Acid 180 mg | Placebo Comparator | Total |
|---|---|---|---|
| Female | 3361 | 3379 | 6740 |
| Male | 3631 | 3599 | 7230 |
| Ethnicity (NIH/OMB)(Participants) | Bempedoic Acid 180 mg | Placebo Comparator | Total |
|---|---|---|---|
| Hispanic or Latino | 1190 | 1143 | 2333 |
| Not Hispanic or Latino | 5802 | 5835 | 11637 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bempedoic Acid 180 mg | Placebo Comparator | Total |
|---|---|---|---|
| American Indian or Alaska Native | 240 | 247 | 487 |
| Asian | 130 | 136 | 266 |
| Native Hawaiian or Other Pacific Islander | 20 | 17 | 37 |
| Black or African American | 156 | 172 | 328 |
| White | 6397 | 6335 | 12732 |
| More than one race | 48 | 70 | 118 |
| Unknown or Not Reported | 1 | 1 | 2 |
Showing the first 100 of 1,332 sites across 32 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Nov 2022, 70 months.
Results were first posted in Jan 2024, 1 year 1 month after primary completion.
Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's 70 months is above that.
Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid